Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11113MR)

This product GTTS-WQ11113MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11113MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14685MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ9339MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ1072MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ11477MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ1979MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ3057MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ2329MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ12415MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW